June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
PROSE treatment for Ocular Surface Disease in patients with history of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
Author Affiliations & Notes
  • Thanos Papakostas
    Ophthalmology, Massachusetts Eye & Ear Infirmary, Boston, MA
  • Hong-Gam Le
    Boston Foundation for Sight, Needham, MA
  • James Chodosh
    Ophthalmology, Massachusetts Eye & Ear Infirmary, Boston, MA
  • Deborah Jacobs
    Ophthalmology, Massachusetts Eye & Ear Infirmary, Boston, MA
    Boston Foundation for Sight, Needham, MA
  • Footnotes
    Commercial Relationships Thanos Papakostas, None; Hong-Gam Le, None; James Chodosh, Alcon (C), Allergan (C), 3-V Biosciences (C), Novabay (C); Deborah Jacobs, Boston Foundation for Sight, 501(c)3 (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5429. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thanos Papakostas, Hong-Gam Le, James Chodosh, Deborah Jacobs; PROSE treatment for Ocular Surface Disease in patients with history of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5429. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To report the visual outcomes with prosthetic rehabilitation of the ocular surface ecosystem (PROSE) treatment in patients with ocular surface disease (OSD) related to to SJS/ TEN.

Methods: Retrospective medical record review of 167 eyes of 86 patients with SJS/TEN who received PROSE treatment 1/1/06 - 7/01/11. Etiology, findings, previous interventions, change in visual acuity and the visual function of the patients based on the NEI-VFQ 25 questionnaire as well as duration of follow-up are reported. Friedman test with Dunn’s post-hoc test for multiple comparisons was used for statistical analysis.

Results: 35 males and 51 females with history of SJS/TENS were treated. Most common reported etiologies for SJS/TENS were penicillins (n=15), lamotrigine (n=11) and ibuprofen (n=6). Mean age at time of treatment was 31.12 years. The median visual acuity at the initial visit was 20/60 (0.48 logMAR), while the visual acuity at completion of customization was 20/25 (0.096 logMAR, p<0.001). The visual acuity at the end of the follow-up was 20/25 (0.096 logMAR, p>0.05, in comparison with visual acuity at the completion of customization) . There was a significant improvement in the visual function of the patients based on the NEI-VFQ 25 questionnaire (47.7 points at baseline vs 71 points at 6 months, p<0.001). In addition, there was also an improvement in the self reported general health of the patients (56 points at baseline vs 65 points at 6 months, p<0.01). Mean duration of follow-up was 16.32 months.

Conclusions: PROSE treatment offers sustained improvement in visual acuity and visual function in patients with OSD related to SJS/TEN.

Keywords: 479 cornea: clinical science  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×